Eli Lilly Secures US Weight Loss Dominance as Pipeline Expands

Eli Lilly (NYSE: LLY) has emerged as the leading provider of weight loss medications in the United States, securing a 60% market share. This growth comes as rival Novo Nordisk's share has slipped to 39%, a shift attributed to Lilly's heavy investment in manufacturing capacity and clinical data showing greater weight loss efficacy. The company's current financial surge is driven by its tirzepatide-based portfolio, comprising Zepbound for obesity and Mounjaro for type 2 diabetes. These dual GIP/GLP-1 receptor agonists generated more than $11 billion in the most recent quarter. This performance propelled Lilly's total quarterly revenue to over $19 billion, representing a 43% year-over-year increase. Lilly is further diversifying its offerings with the recent regulatory approval of Foundayo, an oral weight loss medication. Foundayo holds a strategic advantage over Novo Nordisk's oral Wegovy, as it can be administered with food and beverages, whereas the competitor's product requires an empty stomach. Looking forward, the company is banking on retatrutide to cement its market leadership. This candidate targets three hormonal pathways—GIP, GLP-1, and glucagon—and has shown promising results in phase 3 trials for weight loss and osteoarthritis, resulting in a weight decrease of over 28% over 68 weeks. Lilly expects to complete seven retatrutide phase 3 trials for obesity and diabetes this year. While Zepbound has already demonstrated a 20% average weight loss compared to Wegovy's 13% in head-to-head trials, the introduction of retatrutide could further widen the efficacy gap and solidify Lilly's position in the multi-billion dollar weight loss market.